Pulmonary fungal infections- recent updates

1.

Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2006;42(6):822–5. doi:10.1086/500405.

2.

Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci. 2012;1272:31–9. doi:10.1111/j.1749-6632.2012.06805.x.PubMed

3.

Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30. doi:10.1111/j.1749-6632.2012.06829.x.PubMed

4.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–64. doi:10.1016/j.jinf.2012.08.003.PubMed

5.

Kurosawa M, Yonezumi M, Hashino S, Tanaka J, Nishio M, Kaneda M, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748–57. doi:10.1007/s12185-012-1210-y.PubMed

6.

Racil Z, Weinbergerova B, Kocmanova I, Muzik J, Kouba M, Drgona L, et al. Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009. Int J Infect Dis: IJID : Off Publ Int Soc Infect Dis. 2013;17(2):e101–9. doi:10.1016/j.ijid.2012.09.004.

7.

Garnaud C, Brenier-Pinchart MP, Thiebaut-Bertrand A, Hamidfar R, Quesada JL, Bosseray A, et al. Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital. J Infect. 2012;65(6):559–67. doi:10.1016/j.jinf.2012.08.006.PubMed

8.

Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol. 2012;31(6):991–7. doi:10.1007/s10096-011-1397-5.

9.

Singh N, Husain S. Practice ASTIDCo. Aspergillosis in solid organ transplantation. Am J Transplant : Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(4):228–41. doi:10.1111/ajt.12115.

10.

Egli A, Fuller J, Humar A, Lien D, Weinkauf J, Nador R, et al. Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation. 2012;94(4):403–10. doi:10.1097/TP.0b013e31825992f0.PubMed

11.

Hedayati MT, Khodavaisy S, Alialy M, Omran SM, Habibi MR. Invasive aspergillosis in intensive care unit patients in Iran. Acta Medica. 2013;56(2):52–6.PubMed

12.

Dutkiewicz R, Hage CA. Aspergillus infections in the critically ill. Proc Am Thorac Soc. 2010;7(3):204–9. doi:10.1513/pats.200906-050AL.PubMed

13.•

Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC infectious diseases. 2013;13:29. doi:10.1186/1471-2334-13-29. This is a large retrospective study of 6,424 patients with IA that demonstrated that patients with non-traditional risk factors, specifically non-neutropenic critically ill patients, are at risk for IA (6.7 % of the sample).PubMedCentralPubMed

14.

Gustot T, Maillart E, Bocci M, Surin R, Trepo E, Degre D, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol. 2014;60(2):267–74. doi:10.1016/j.jhep.2013.09.011.PubMed

15.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis:Off Publ Infect Dis Soc Am. 2008;46(12):1813–21. doi:10.1086/588660.

16.

Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12(2):310–50.PubMedCentralPubMed

17.

Choi SH, Kang ES, Eo H, Yoo SY, Kim JH, Yoo KH, et al. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2013;60(2):316–22. doi:10.1002/pbc.24363.PubMed

18.

Dufresne SF, Datta K, Li X, Dadachova E, Staab JF, Patterson TF, et al. Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. PLoS ONE. 2012;7(8):e42736. doi:10.1371/journal.pone.0042736.PubMedCentralPubMed

19.

Wingard JR. Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation? Best Pract Res Clin Haematol. 2012;25(4):487–91. doi:10.1016/j.beha.2012.10.013.PubMedCentralPubMed

20.

Ku NS, Han SH, Choi JY, Kim SB, Kim HW, Jeong SJ, et al. Diagnostic value of the serum galactomannan assay for invasive aspergillosis: it is less useful in non-haematological patients. Scand J Infect Dis. 2012;44(8):600–4. doi:10.3109/00365548.2012.657672.PubMed

21.

Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis:Off Publ Infecti Dis Soc Am. 2006;42(10):1417–27. doi:10.1086/503427.

22.

Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Iqbal S. Serum galactomannan assay for diagnosis of probable invasive Aspergillosis in acute leukemia and hematopoietic stem cell transplantation. IndianJ Med Paediatr Oncol: Off J Indian Soc Med Paediatr Oncol. 2013;34(2):74–9. doi:10.4103/0971-5851.116181.

23.

Tanase AD, Colita A, Marculescu A, Berteanu C, Streinu Cercel A, Stoica M, et al. Using the galactomannan antigen assay in the diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Romanian journal of morphology and embryology =. Revue roumaine de morphologie et embryologie. 2012;53(2):379–82.PubMed

24.

Khanna S, Oberoi JK, Datta S, Aggarwal S, Wattal C. Variables affecting the performance of galactomannan assay in high-risk patients at a tertiary care centre in India. Indian J Med Microbiol. 2013;31(1):34–9. doi:10.4103/0255-0857.108717.PubMed

25.

Nosari AM, Caira M, Pioltelli ML, Fanci R, Bonini A, Cattaneo C, et al. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis. 2013;19(8):757–62. doi:10.1111/1469-0691.12014.

26.

Badiee P, Alborzi A, Karimi M, Pourabbas B, Haddadi P, Mardaneh J, et al. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Countries. 2012;6(4):352–7.

27.

Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses. 2013;56(4):442–8. doi:10.1111/myc.12048.PubMed

28.

White PL, Jones T, Whittle K, Watkins J, Barnes RA. Comparison of galactomannan enzyme immunoassay performance levels when testing serum and plasma samples. Clin Vaccine Immunol : CVI. 2013;20(4):636–8. doi:10.1128/CVI.00730-12.PubMedCentralPubMed

29.

Brownback KR, Pitts LR, Simpson SQ. Utility of galactomannan antigen detection in bronchoalveolar lavage fluid in immunocompromised patients. Mycoses. 2013;56(5):552–8. doi:10.1111/myc.12074.PubMed

30.

D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol. 2012;50(4):1258–63. doi:10.1128/JCM.06423-11.PubMedCentralPubMed

31.

de Mol M, de Jongste JC, van Westreenen M, Merkus PJ, de Vries AH, Hop WC, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr Pulmonol. 2013;48(8):789–96. doi:10.1002/ppul.22670.PubMed

32.

Kono Y, Tsushima K, Yamaguchi K, Kurita N, Soeda S, Fujiwara A, et al. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respir Med. 2013;107(7):1094–100. doi:10.1016/j.rmed.2013.04.007.PubMed

33.

Reinwald M, Spiess B, Heinz WJ, Vehreschild JJ, Lass-Florl C, Kiehl M, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012;89(2):120–7. doi:10.1111/j.1600-0609.2012.01806.x.PubMed

34.

Tabarsi P, Soraghi A, Marjani M, Zandian P, Baghaei P, Najafizadeh K, et al. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant : Off J Middle East Soc Organ Transplant. 2012;10(3):278–81.

35.••

Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PloS one. 2012;7(8):e43347. doi:10.1371/journal.pone.0043347. This is a meta-analysis of 16 studies including 614 patients with proven or probable IA demonstrated very good performance of BAL GM in detecting IA (sensitivity (85 %) and specificity (86 %).PubMedCentralPubMed

36.

He H, Li Q, Chang S, Ding L, Sun B, Li F, et al. Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis. Chin Med J. 2014;127(1):23–8.PubMed

37.

Zhang XB, Chen GP, Lin QC, Lin X, Zhang HY, Wang JH. Bronchoalveolar lavage fluid galactomannan detection for diagnosis of invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. Med Mycol. 2013;51(7):688–95. doi:10.3109/13693786.2013.777162.PubMed

38.

Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012;50(7):2330–6. doi:10.1128/JCM.06513-11.PubMedCentralPubMed

39.

Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;57(7):1001–4. doi:10.1093/cid/cit393.

40.

Hoenigl M, Seeber K, Koidl C, Buzina W, Wolfler A, Duettmann W, et al. Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Mycoses. 2013;56(4):471–6. doi:10.1111/myc.12060.PubMed

41.

Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis :Off Publ Infect Dis Soc Am. 2005;40(12):1762–9. doi:10.1086/429921.

42.

Metan G, Agkus C, Nedret Koc A, Elmali F, Finkelman MA. Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses. 2012;55(4):366–71. doi:10.1111/j.1439-0507.2011.02131.x.PubMed

43.

Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, et al. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrobial Chemother. 2012;67(7):1746–8. doi:10.1093/jac/dks111.

44.

Vergidis P, Razonable RR, Wheat LJ, Estes L, Caliendo AM, Baden LR, et al. Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. J Clin Microbiol. 2014;52(6):2199–201. doi:10.1128/JCM.00285-14.PubMed

45.

Fontana C, Gaziano R, Favaro M, Casalinuovo I, Pistoia E, Di Francesco P. 1–3)-beta-D-Glucan vs Galactomannan Antigen in Diagnosing Invasive Fungal Infections (IFIs. Open Microbiol J. 2012;6:70–3. doi:10.2174/1874285801206010070.PubMedCentralPubMed

46.

Gerlinger MP, Rousselot P, Rigaudeau S, Billon C, Touratier S, Castaigne S, et al. False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect. 2012;42(1):10–4. doi:10.1016/j.medmal.2011.10.018.PubMed

47.

Perfect JR. Fungal diagnosis: how do we do it and can we do better? Curr Med Res Opin. 2013;29 Suppl 4:3–11. doi:10.1185/03007995.2012.761134.PubMed

48.

Riviere S, Denis B, Bougnoux ME, Lanternier F, Lecuit M, Lortholary O. Serum Aspergillus galactomannan for the management of disseminated histoplasmosis in AIDS. AmJTrop Med Hyg. 2012;87(2):303–5. doi:10.4269/ajtmh.2012.12-0119.

49.

Vergidis P, Walker RC, Kaul DR, Kauffman CA, Freifeld AG, Slagle DC, et al. False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transplant Infect Dis: Off J Transplant Soc. 2012;14(2):213–7. doi:10.1111/j.1399-3062.2011.00675.x.

50.

Van Der Veer J, Lewis RJ, Emtiazjoo AM, Allen SD, Wheat LJ, Hage CA. Cross-reactivity in the Platelia Aspergillus enzyme immunoassay caused by blastomycosis. Med Mycol. 2012;50(4):396–8. doi:10.3109/13693786.2011.608172.

51.

Roilides E, Pana ZD. Application of diagnostic markers to invasive aspergillosis in children. Ann N Y Acad Sci. 2012;1272:1–8. doi:10.1111/j.1749-6632.2012.06828.x.PubMed

52.

Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(6):750–70. doi:10.1093/cid/ciq206.

53.

Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7–15. doi:10.1128/JCM.05267-11.PubMedCentralPubMed

54.

Theel ES, Jespersen DJ, Iqbal S, Bestrom JE, Rollins LO, Misner LJ, et al. Detection of (1, 3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1–2):33–41. doi:10.1007/s11046-012-9579-y.PubMed

55.

Acosta J, Catalan M, del Palacio-Perez-Medel A, Montejo JC, De-La-Cruz-Bertolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol. 2012;31(5):721–31. doi:10.1007/s10096-011-1365-0.

56.

Koo S, Kubiak DW, Issa NC, Dietzek A, Boukedes S, Camp PC, et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation. 2012;94(3):281–6. doi:10.1097/TP.0b013e318255f864.PubMed

57.

Racil Z, Kocmanova I, Toskova M, Winterova J, Lengerova M, Timilsina S, et al. Reactivity of the 1,3-beta-D-glucan assay during bacteraemia: limited evidence from a prospective study. Mycoses. 2013;56(2):101–4. doi:10.1111/j.1439-0507.2012.02210.x.PubMed

58.

Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519–28. doi:10.1016/S1473-3099(13)70076-8.PubMed

59.

Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89–96. doi:10.1016/S1473-3099(09)70019-2.PubMed

60.

Schwarzinger M, Sagaon-Teyssier L, Cabaret O, Bretagne S, Cordonnier C, Investigators P. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS ONE. 2013;8(6):e65776. doi:10.1371/journal.pone.0065776.PubMedCentralPubMed

61.

Reinwald M, Hummel M, Kovalevskaya E, Spiess B, Heinz WJ, Vehreschild JJ, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrobial Chemother. 2012;67(9):2260–7. doi:10.1093/jac/dks208.

62.

Kim SH, Park C, Kwon EY, Shin NY, Kwon JC, Park SH, et al. Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis. J Korean Med Sci. 2012;27(1):10–5. doi:10.3346/jkms.2012.27.1.10.PubMedCentralPubMed

63.

Springer J, Morton CO, Perry M, Heinz WJ, Paholcsek M, Alzheimer M, et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol. 2013;51(5):1445–50. doi:10.1128/JCM.03322-12.PubMedCentralPubMed

64.

Rogers TR, Morton CO, Springer J, Conneally E, Heinz W, Kenny C, et al. Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. Br J Haematol. 2013;161(4):517–24. doi:10.1111/bjh.12285.PubMed

65.

Nabili M, Shokohi T, Janbabaie G, Hashemi-Soteh MB, Ali-Moghaddam K, Aghili SR. Detection of invasive aspergillosis in bone marrow transplant recipients using real-time PCR. J Global Infect Dis. 2013;5(2):68–75. doi:10.4103/0974-777X.112296.

66.

Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis. Crit Rev Microbiol. 2013. doi:10.3109/1040841X.2013.804033.PubMed

67.

Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol. 2012;50(11):3652–8. doi:10.1128/JCM.00942-12.PubMedCentralPubMed

68.

Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Visualized Exp : JoVE. 2012 (61). doi:10.3791/3721.

69.

Koo S., Thomas H. R., Rearden P., Comolli J., Baden L., R., Marty F. M. An Aspergillus fumigatus (AF)-specific Breath Volatile Organic Compound (VOC) Profile is Diagnostic of Invasive Aspergillosis (IA). 2013.

70.

Shi LN, Li FQ, Huang M, Lu JF, Kong XX, Wang SQ, et al. Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis. BMC Microbiol. 2012;12:11. doi:10.1186/1471-2180-12-11.PubMedCentralPubMed

71.

Du C, Wingard JR, Cheng S, Nguyen MH, Clancy CJ. Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2012;18(12):1927–34. doi:10.1016/j.bbmt.2012.07.013.

72.

Domingo MP, Colmenarejo C, Martinez-Lostao L, Mullbacher A, Jarne C, Revillo MJ, et al. Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagn Microbiol Infect Dis. 2012;73(1):57–64. doi:10.1016/j.diagmicrobio.2012.01.012.PubMed

73.

Zhang XZ, Huang XE, Xu YL, Zhang XQ, Su AL, Shen ZS. Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pacific J Cancer Prev : APJCP. 2012;13(5):2415–8.

74.

Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Eur J Clin Microbiol infect Dis: Off Publ Eur Soc Clin Microbiol. 2012;31(6):1173–9. doi:10.1007/s10096-011-1425-5.

75.

Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis: IJID : Off Publ Int Soc Infect Dis. 2012;16(2):e76–81. doi:10.1016/j.ijid.2011.10.004.

76.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2008;46(3):327–60. doi:10.1086/525258.

77.

Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses. 2013;56(3):304–10. doi:10.1111/myc.12023.PubMed

78.

Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2012;55(8):1080–7. doi:10.1093/cid/cis599.

79.

Carvalho A, Cunha C, Bistoni F, Romani L. Immunotherapy of aspergillosis. Clin Microbiol Infect : Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(2):120–5. doi:10.1111/j.1469-0691.2011.03681.x.

80.

Knox KS, Hage CA. Histoplasmosis. Proc Am Thorac Soc. 2010;7(3):169–72. doi:10.1513/pats.200907-069AL.PubMed

81.••

Assi M, Martin S, Wheat LJ, Hage C, Freifeld A, Avery R, et al. Histoplasmosis after solid organ transplant. Clin infect Dis: Off Publ Infect Dis Soc Am. 2013;57(11):1542–9. doi:10.1093/cid/cit593. In this case series of 152 solid organ transplant recipients, it was found that the first year after transplant is the period of highest risk for histoplasmosis (34%).

82.

Grim SA, Proia L, Miller R, Alhyraba M, Costas-Chavarri A, Oberholzer J, et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transplant Infect Dis:Off J Transplant Soc. 2012;14(1):17–23. doi:10.1111/j.1399-3062.2011.00658.x.

83.

Centers for Disease Control and Prevention (CDC). (2013, October 25). Histoplasmosis in a State Where It Is Not Known to Be Endemic —Montana, 2012–2013. MMWR. Morbidity and Mortality Weekly Reports. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6242a2.htm

84.

Pan B, Chen M, Pan W, Liao W. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. Mycoses. 2013;56(3):212–21. doi:10.1111/myc.12029.PubMed

85.

Mukhopadhyay S, Doxtader EE. Visibility of Histoplasma within histiocytes on hematoxylin and eosin distinguishes disseminated histoplasmosis from other forms of pulmonary histoplasmosis. Hum Pathol. 2013;44(10):2346–52. doi:10.1016/j.humpath.2013.05.024.PubMed

86.

Gailey MP, Klutts JS, Jensen CS. Fine-needle aspiration of histoplasmosis in the era of endoscopic ultrasound and endobronchial ultrasound: cytomorphologic features and correlation with clinical laboratory testing. Cancer Cytopathol. 2013;121(9):508–17. doi:10.1002/cncy.21298.PubMed

87.

Arango-Bustamante K, Restrepo A, Cano LE, de Bedout C, Tobon AM, Gonzalez A. Diagnostic value of culture and serological tests in the diagnosis of histoplasmosis in HIV and non-HIV Colombian patients. AmJTrop Med Hyg. 2013;89(5):937–42. doi:10.4269/ajtmh.13-0117.

88.

Hage CA, Knox KS, Wheat LJ. Endemic mycoses: overlooked causes of community acquired pneumonia. Respir Med. 2012;106(6):769–76. doi:10.1016/j.rmed.2012.02.004.PubMed

89.

Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(5):448–54. doi:10.1093/cid/cir435.

90.••

Hage CA, Kirsch EJ, Stump TE, Kauffman CA, Goldman M, Connolly P, et al. Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clinical and vaccine immunology : CVI. 2011;18(4):661–6. doi:10.1128/CVI.00389-10. This analysis of 158 patients with disseminated histoplasmosis showed that Histoplasma urine Ag is more sensitive in immunocompromised (93.1 %), AIDS (94.6 %), and severely ill (100 %) patients than in immunocompetent patients (73.3 %).PubMedCentralPubMed

91.

Dantas KC, Freitas RS, Moreira AP, Silva MV, Benard G, Vasconcellos C, et al. The use of nested Polymerase Chain Reaction (nested PCR) for the early diagnosis of Histoplasma capsulatum infection in serum and whole blood of HIV-positive patients. An Bras Dermatol. 2013;88(1):141–3.PubMedCentralPubMed

92.

Scheel CM, Zhou Y, Theodoro RC, Abrams B, Balajee SA, Litvintseva AP. Development of a loop-mediated isothermal amplification method for detection of Histoplasma capsulatum DNA in clinical samples. J Clin Microbiol. 2014;52(2):483–8. doi:10.1128/JCM.02739-13.PubMedCentralPubMed

93.

Elias NA, Cuestas ML, Sandoval M, Poblete G, Lopez-Daneri G, Jewtuchowicz V, et al. Rapid identification of Histoplasma capsulatum directly from cultures by multiplex PCR. Mycopathologia. 2012;174(5–6):451–6. doi:10.1007/s11046-012-9567-2.PubMed

94.

Koepsell SA, Hinrichs SH, Iwen PC. Applying a real-time PCR assay for Histoplasma capsulatum to clinically relevant formalin-fixed paraffin-embedded human tissue. J Clin Microbiol. 2012;50(10):3395–7. doi:10.1128/JCM.01705-12.PubMedCentralPubMed

95.

Wheat LJ, Wass J, Norton J, Kohler RB, French ML. Cavitary histoplasmosis occurring during two large urban outbreaks. . Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine. 1984;63(4):201–9.PubMed

96.••

Myint T, Anderson AM, Sanchez A, Farabi A, Hage C, Baddley JW, et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine. 2014;93(1):11–8. doi:10.1097/MD.0000000000000016. This prospective cohort of 97 HIV/AIDS patients with histoplasmosis showed that discontinuation of antifungal therapy after one year of treatment was safe if HIV/AIDS was well controlled, Histoplasma urine Ag was <2 ng/mL and there was no CNS involvement.PubMed

97.

Brilhante RS, Caetano EP, Sidrim JJ, Cordeiro RA, Camargo ZP, Fechine MA, et al. Ciprofloxacin shows synergism with classical antifungals against Histoplasma capsulatum var capsulatum and Coccidioides posadasii. Mycoses. 2013;56(3):397–401. doi:10.1111/myc.12025.PubMed

98.

Das R, McNary J, Fitzsimmons K, Dobraca D, Cummings K, Mohle-Boetani J, et al. Occupational coccidioidomycosis in California: outbreak investigation, respirator recommendations, and surveillance findings. J Occup Environ Med / Am Coll Occup Environ Med. 2012;54(5):564–71. doi:10.1097/JOM.0b013e3182480556.

99.

Centers for Disease Control and Prevention (CDC). (2013, March 29). Increase in Reported Coccidioidomycosis — United States, 1998–2011. MMWR. Morbidity and Mortality Weekly Reports. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a1.htm

100.

Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev. 2013;26(3):505–25. doi:10.1128/CMR.00005-13.PubMedCentralPubMed

101.

Huang JY, Bristow B, Shafir S, Sorvillo F. Coccidioidomycosis-associated Deaths, United States, 1990–2008. Emerg Infect Dis. 2012;18(11):1723–8. doi:10.3201/eid1811.120752.PubMedCentralPubMed

102.

Seitz AE, Prevots DR, Holland SM. Hospitalizations associated with disseminated coccidioidomycosis, Arizona and California, USA. Emerg Infect Dis. 2012;18(9):1476–9. doi:10.3201/eid1809.120151.PubMedCentralPubMed

103.

Blair JE, Mendoza N, Force S, Chang YH, Grys TE. Clinical specificity of the enzyme immunoassay test for coccidioidomycosis varies according to the reason for its performance. Clin Vaccine Immunol: CVI. 2013;20(1):95–8. doi:10.1128/CVI.00531-12.PubMedCentralPubMed

104.

Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect. 2001;16(4):242–50.PubMed

105.

Mendoza N, Blair JE. The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(4):1034–9. doi:10.1111/ajt.12144.

106.

Thompson GR, Sharma S, Bays DJ, Pruitt R, Engelthaler DM, Bowers J, et al. Coccidioidomycosis: adenosine deaminase levels, serologic parameters, culture results, and polymerase chain reaction testing in pleural fluid. Chest. 2013;143(3):776–81. doi:10.1378/chest.12-1312.PubMedCentralPubMed

107.

Johnson R, Kernerman SM, Sawtelle BG, Rastogi SC, Nielsen HS, Ampel NM. A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis. Mycopathologia. 2012;174(5–6):353–8. doi:10.1007/s11046-012-9555-6.PubMed

108.

Thompson 3rd GR, Bays DJ, Johnson SM, Cohen SH, Pappagianis D, Finkelman MA. Serum (1- > 3)-beta-D-glucan measurement in coccidioidomycosis. J Clin Microbiol. 2012;50(9):3060–2. doi:10.1128/JCM.00631-12.PubMedCentralPubMed

109.

Nesbit LA, Knox KS, Nguyen CT, Roesch J, Wheat LJ, Johnson SM, et al. Immunological characterization of bronchoalveolar lavage fluid in patients with acute pulmonary coccidioidomycosis. J Infect dis. 2013;208(5):857–63. doi:10.1093/infdis/jit246.PubMed

110.

Azadeh N, Chang YH, Kusne S, Vikram HR, Seville MT, Orenstein R, et al. The impact of early and brief corticosteroids on the clinical course of primary pulmonary coccidioidomycosis. J Infect. 2013;67(2):148–55. doi:10.1016/j.jinf.2013.04.001.PubMed

111.

Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation. 2011;92(7):717–21. doi:10.1097/TP.0b013e31822e6e9a.PubMed

112.

Taroumian S, Knowles SL, Lisse JR, Yanes J, Ampel NM, Vaz A, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res. 2012;64(12):1903–9. doi:10.1002/acr.21784.

113.

Hurtgen BJ, Hung CY, Ostroff GR, Levitz SM, Cole GT. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect Immun. 2012;80(11):3960–74. doi:10.1128/IAI.00566-12.PubMedCentralPubMed

114.

Litvinov IV, St-Germain G, Pelletier R, Paradis M, Sheppard DC. Endemic human blastomycosis in Quebec, Canada, 1988–2011. Epidemiol Infect. 2013;141(6):1143–7. doi:10.1017/S0950268812001860.PubMed

115.

Roy M, Benedict K, Deak E, Kirby MA, McNiel JT, Sickler CJ, et al. A large community outbreak of blastomycosis in Wisconsin with geographic and ethnic clustering. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;57(5):655–62. doi:10.1093/cid/cit366.

116.

Connolly P, Hage CA, Bariola JR, Bensadoun E, Rodgers M, Bradsher Jr RW, et al. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vaccine Immunol: CVI. 2012;19(1):53–6. doi:10.1128/CVI.05248-11.PubMedCentralPubMed

117.

Richer SM, Smedema ML, Durkin MM, Brandhorst TT, Hage CA, Connolly PA, et al. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein BAD-1. Clin and Vaccine Immunol: CVI. 2014;21(2):143–6. doi:10.1128/CVI.00597-13.PubMedCentralPubMed

118.

Sidamonidze K, Peck MK, Perez M, Baumgardner D, Smith G, Chaturvedi V, et al. Real-time PCR assay for identification of Blastomyces dermatitidis in culture and in tissue. J Clin Microbiol. 2012;50(5):1783–6. doi:10.1128/JCM.00310-12.PubMedCentralPubMed

119.

Recht LD, Philips JR, Eckman MR, Sarosi GA. Self-limited blastomycosis: a report of thirteen cases. Am Rev Respir Dis. 1979;120(5):1109–12.PubMed

120.

Klein BS, Vergeront JM, Weeks RJ, Kumar UN, Mathai G, Varkey B, et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med. 1986;314(9):529–34. doi:10.1056/NEJM198602273140901.PubMed

121.

Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis: Off Publ InfectDis Soc Am. 2008;46(12):1801–12. doi:10.1086/588300.

122.

Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128. doi:10.1164/rccm.2008-740ST.PubMed

123.

Dismukes WE, Bradsher Jr RW, Cloud GC, Kauffman CA, Chapman SW, George RB, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med. 1992;93(5):489–97.PubMed

124.

Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53(4):1648–51. doi:10.1128/AAC.01148-07.PubMedCentralPubMed

125.

Busey JF. Blastomycosis. 3. A comparative study of 2-hydroxystilbamidine and amphotericin B therapy. Am Rev Respir Dis. 1972;105(5):812–8.PubMed

126.

Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis. 1969;99(6):895–902.PubMed

127.

Abernathy RS. Amphotericin therapy of North American blastomycosis. Antimicrob Agents Chemother. 1966;6:208–11.PubMed

128.

Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med. 1993;329(17):1231–6. doi:10.1056/NEJM199310213291704.PubMed

129.

Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA. Blastomycosis in northeast Tennessee. Chest. 1998;114(2):436–43.PubMed

130.

Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol. 2001;5(1):1–9. doi:10.1053/adpa.2001.21473.PubMed

131.

Lahm T, Neese S, Thornburg AT, Ober MD, Sarosi GA, Hage CA. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest. 2008;133(6):1478–80. doi:10.1378/chest.07-2778.PubMed

132.

Plamondon M, Lamontagne F, Allard C, Pepin J. Corticosteroids as adjunctive therapy in severe blastomycosis-induced acute respiratory distress syndrome in an immunosuppressed patient. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2010;51(1):e1–3. doi:10.1086/653429.

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pulmonary fungal infections- recent updates

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Primary mediastinal B-cell lymphoma

The role of endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal processes other than lung cancer

Electronic nicotine delivery systems for smoking cessation: where are we?

Gastroesophageal reflux disease and the lung transplant recipient